NCT05405660Phase 2Completed

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-06-12Actual

Enrollment · participants196Actual

Source updated2025-11-06Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-11-06 · 1 field changed

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Study details

Conditions studied

Chronic Inducible Urticaria

Treatments or interventions studied

barzolvolimabBiologicalAlso known as CDX-0159
Matching PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Percentage of patients with a negative provocation test at week 12; description: Percentage of patients with a negative provocation test for Cold Inducible Urticaria \[ColdU\] or Symptomatic Dermographism \[SD\]) at week 12 * For ColdU patients, a negative provocation test is defined as absence of wheals at the provocation site within 10 min at ≤ 4°C after provocation using TempTest® * For SD patients, a negative provocation test is defined as absence of wheals at the provocation site within 10 min at 0 pins after provocation using the FricTest®; timeFrame: From baseline to week 12

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history